Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
Public ClinicalTrials.gov record NCT00800683. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 vs. Placebo, DB, Parallel Group, Randomized, Insulin Background Inclusive
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
to determine safety, efficacy and tolerability of BI 1356 versus placebo
Study identification
- NCT ID
- NCT00800683
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 133 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2008 (Type not available)
- Primary completion
- Jan 2011 (Actual)
- Completion
- Not listed
- Last update posted
- May 20, 2014
Started 2008
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1218.43.10027 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1218.43.10011 Boehringer Ingelheim Investigational Site | Chula Vista | California | — | — |
| 1218.43.10006 Boehringer Ingelheim Investigational Site | Riverside | California | — | — |
| 1218.43.10021 Boehringer Ingelheim Investigational Site | Whittier | California | — | — |
| 1218.43.10013 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 1218.43.10009 Boehringer Ingelheim Investigational Site | West Palm Beach | Florida | — | — |
| 1218.43.10018 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 1218.43.10022 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1218.43.10015 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 1218.43.10016 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 1218.43.10003 Boehringer Ingelheim Investigational Site | Great Neck | New York | — | — |
| 1218.43.10004 Boehringer Ingelheim Investigational Site | The Bronx | New York | — | — |
| 1218.43.10020 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1218.43.10019 Boehringer Ingelheim Investigational Site | Delaware | Ohio | — | — |
| 1218.43.10008 Boehringer Ingelheim Investigational Site | Mentor | Ohio | — | — |
| 1218.43.10005 Boehringer Ingelheim Investigational Site | Bethlehem | Pennsylvania | — | — |
| 1218.43.10007 Boehringer Ingelheim Investigational Site | Carlisle | Pennsylvania | — | — |
| 1218.43.10001 Boehringer Ingelheim Investigational Site | Providence | Rhode Island | — | — |
| 1218.43.10025 Boehringer Ingelheim Investigational Site | Aiken | South Carolina | — | — |
| 1218.43.10023 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 1218.43.10024 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 1218.43.10014 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1218.43.10017 Boehringer Ingelheim Investigational Site | Lufkin | Texas | — | — |
| 1218.43.10010 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00800683, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2014 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00800683 live on ClinicalTrials.gov.